Request Demo
Biocon and Handok link to commercialise Liraglutide in South Korea
License out/inDrug Approval
Biocon will handle Liraglutide’s development, manufacturing and supply. Credit: Poetra.RH / Shutterstock.com.
Biocon biopharmaceuLiraglutideny Biocon has entered an exclusive licence and supply agreement with Handok to commercialise synthetic Liraglutide in South Korea.
A vertically integrated, complex BioconLiraglutide is administered using pre-filled injection pens.Handok designed for chronic weightLiraglutide alongside a reduced-calorie diet and increased physical activity.
Biocon will handle Liraglutide’s develoLiraglutidefacture and supply in South Korea.
Biocon will overseeLiraglutidetory approvals and commercialisation of the product in the market.
Handok’s diabetes care portfolio includes Amaryl, Tenelia and the real-time glucose monitoring device Barozen Fit.
Global contract research organisation IQVIA‘s moving annual total for the fourth quarter of 2023 values the market opportunity for Liraglutide in South Korea at $47m.
BCilostazolandrosuvastatinh Mittal stated: “We are pleChronic Coronary Artery Disease (CAD)tnIschemic Heart Diseaseich will enable patients in South Korea dealing with weight management to gain access to our GLP-1 peptide drug product, synthetic Liraglutide.
“This also aligns with our commitment to expand our portfolio of innovative, affordable medicines to address the unmet needs of patients around the world. We look forward to leveraging Handok’s strong capabilities to help patients in the region better manage their disease.”
In December 2023, Biocon’s subsidiary Biocon Biologics completed the integration of Viatris’ biosimilars business across 31 EuropeaLiraglutide.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.